OSAMU MATSUO

Prof. Dr. OSAMU MATSUO

Kindai University Faculty of Medicine, Osakasayama 589-8511, Japan

Research Focus & Metrics

Academic Career Length

41Years (1986-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
1 February 2008 in Journal of Clinical Investigation
Verified
Journal Article
Closed access
PDF file
YLYang Li
Yang Li
FZFan Zhang
Fan Zhang
NNNobuo Nagai
Nobuo Nagai
ZTZhongshu Tang
Zhongshu Tang
SZShuihua Zhang
Shuihua Zhang
XLXuri Li
Xuri Li
Despite its early discovery and high sequence homology to the other VEGF family members, the biological functions of VEGF-B remain poorly understood. We revealed here a novel function for VEGF-B as a potent inhibitor of apoptosis. Using gene expression profiling of mouse primary aortic smooth muscle cells, and confirming the results by real-time PCR using mouse and rat cell lines, we showed that VEGF-B inhibited the expression of genes encoding the proapoptotic BH3-only proteins and other apoptosis- and cell death–related proteins, including p53 and members of the caspase family, via activation of VEGFR-1. Consistent with this, VEGF-B treatment rescued neurons from apoptosis in the retina and brain in mouse models of ocular neurodegenerative disorders and stroke, respectively. Interestingly, VEGF-B treatment at the dose effective for neuronal survival did not cause retinal neovascularization, suggesting that VEGF-B is the first member of the VEGF family that has a potent antiapoptotic effect while lacking a general angiogenic activity. These findings indicate that VEGF-B may potentially offer a new therapeutic option for the treatment of neurodegenerative diseases.

1 March 2001 in Hepatology
Verified
Journal Article
Open access
PDF file
Masahito ShimizuMasahito Shimizu
Masahito Shimizu
AHAkira Hara
Akira Hara
MOMasataka Okuno
Masataka Okuno
HMHiroyuki Matsuno
Hiroyuki Matsuno
KOKiyotaka Okada
Kiyotaka Okada
HMHideki Mori
Hideki Mori
Urokinase‐type plasminogen activator (uPA) is implicated in the regulation of hepatic regeneration by activating hepatocyte growth factor (HGF). Here, we investigated its role in the hepatic regeneration after Fas‐mediated massive hepatocyte death employing mice deficient in either uPA or its inhibitor, plasminogen activator inhibitor‐1 (PAI‐1). We measured kinetics of hepatic levels of proliferating cell nuclear antigen (PCNA)‐labeling index, plasmin activity, mature HGF, and its phosphorylated receptor, c‐Met. In the genetically targeted and wild‐type mice, hepatocytes fell into the same extent of apoptosis 6 to 12 hours after an intraperitoneal injection with anti‐Fas antibody, as judged from histologic analysis and a histon‐DNA enzyme‐linked immunosorbent assay (ELISA). In the wild‐type mice, mature HGF emerged in the liver 6 hours following anti‐Fas injection, and hepatic PCNA‐labeling index started to increase following 24 hours and peaked at 48 hours. In the uPA−/− mice, emergence of mature HGF was delayed 12 hours and hepatic regeneration peaked at 96 hours. Supplementation with the uPA gene to the uPA−/− mice by in vivo lipofection restored hepatic plasmin levels, and improved a delay in the expression of both mature HGF and phosphorylated c‐Met, accompanying a normal rate of liver regeneration. In contrast, PAI‐1−/− mice showed accelerated liver regeneration; mature HGF emerged as early as 3 hours, and PCNA‐labeling index increased at 24 hours. This accelerated regeneration was abolished by administration with anti‐HGF antibody. These results strongly suggest a physiologic role of uPA in the proteolytic maturation of HGF, and thereby in hepatic regeneration after Fas‐mediated massive hepatocyte death.

1 October 2007 in Cell Biology International
Verified
Journal Article
Closed access
SOSayuri Otaki
Sayuri Otaki
SUShigeru Ueshima
Shigeru Ueshima
KSKohei Shiraishi
Kohei Shiraishi
KSKazuo Sugiyama
Kazuo Sugiyama
SHSuguru Hamada
Suguru Hamada
OSAMU MATSUOOSAMU MATSUO
OSAMU MATSUO

5 July 2002 in Biochemical and Biophysical Research Communications
Verified
Journal Article
Closed access
ALAernout Luttun
Aernout Luttun
KBKoen Brusselmans
Koen Brusselmans
HFHideharu Fukao
Hideharu Fukao
MTMarc Tjwa
Marc Tjwa
SUShigeru Ueshima
Shigeru Ueshima
LMLieve Moons
Lieve Moons

3 March 2013 in Journal of Bone and Mineral Research
Verified
Journal Article
Open access
PDF file
NKNaoyuki Kawao
Naoyuki Kawao
YTYukinori Tamura
Yukinori Tamura
KOKatsumi Okumoto
Katsumi Okumoto
MYMasato Yano
Masato Yano
KOKiyotaka Okada
Kiyotaka Okada
HKHiroshi Kaji
Hiroshi Kaji
The further development in research of bone regeneration is necessary to meet the clinical demand for bone reconstruction. Plasminogen is a critical factor of the tissue fibrinolytic system, which mediates tissue repair in the skin and liver. However, the role of the fibrinolytic system in bone regeneration remains unknown. Herein, we investigated bone repair and ectopic bone formation using plasminogen-deficient (Plg–/–) mice. Bone repair of the femur is delayed in Plg–/– mice, unlike that in the wild-type (Plg+/+) mice. The deposition of cartilage matrix and osteoblast formation were both decreased in Plg–/– mice. Vessel formation, macrophage accumulation, and the levels of vascular endothelial growth factor (VEGF) and transforming growth factor-β (TGF-β) were decreased at the site of bone damage in Plg–/– mice. Conversely, heterotopic ossification was not significantly different between Plg+/+ and Plg–/– mice. Moreover, angiogenesis, macrophage accumulation, and the levels of VEGF and TGF-β were comparable between Plg+/+ and Plg–/– mice in heterotopic ossification. Our data provide novel evidence that plasminogen is essential for bone repair. The present study indicates that plasminogen contributes to angiogenesis related to macrophage accumulation, TGF-β, and VEGF, thereby leading to the enhancement of bone repair.

31 December 2014 in Diabetes
Verified
Journal Article
Open access
PDF file
YTYukinori Tamura
Yukinori Tamura
NKNaoyuki Kawao
Naoyuki Kawao
MYMasato Yano
Masato Yano
KOKiyotaka Okada
Kiyotaka Okada
KOKatsumi Okumoto
Katsumi Okumoto
HKHiroshi Kaji
Hiroshi Kaji
Long-term use of glucocorticoids (GCs) causes numerous adverse effects, including glucose/lipid abnormalities, osteoporosis, and muscle wasting. The pathogenic mechanism, however, is not completely understood. In this study, we used plasminogen activator inhibitor-1 (PAI-1)–deficient mice to explore the role of PAI-1 in GC-induced glucose/lipid abnormalities, osteoporosis, and muscle wasting. Corticosterone markedly increased the levels of circulating PAI-1 and the PAI-1 mRNA level in the white adipose tissue of wild-type mice. PAI-1 deficiency significantly reduced insulin resistance and glucose intolerance but not hyperlipidemia induced by GC. An in vitro experiment revealed that active PAI-1 treatment inhibits insulin-induced phosphorylation of Akt and glucose uptake in HepG2 hepatocytes. However, this was not observed in 3T3-L1 adipocytes and C2C12 myotubes, indicating that PAI-1 suppressed insulin signaling in hepatocytes. PAI-1 deficiency attenuated the GC-induced bone loss presumably via inhibition of apoptosis of osteoblasts. Moreover, the PAI-1 deficiency also protected from GC-induced muscle loss. In conclusion, the current study indicated that PAI-1 is involved in GC-induced glucose metabolism abnormality, osteopenia, and muscle wasting in mice. PAI-1 may be a novel therapeutic target to mitigate the adverse effects of GC.